Literature DB >> 911615

Biological determinants of propranolol disposition in normal subjects and patients with cirrhosis [proceedings].

R A Branch, D M Kornhauser, D G Shand, G R Wilkinson, A J Wood.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 911615     DOI： 10.1111/j.1365-2125.1977.tb00802.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  6 in total

Review 1.  Hepatic first-pass metabolism in liver disease.

Authors:  T F Blaschke; P C Rubin
Journal:  Clin Pharmacokinet       Date:  1979 Nov-Dec       Impact factor: 6.447

2.  beta-blocker plasma concentrations and inflammatory disease: clinical implications.

Authors:  R E Schneider; H Bishop
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

3.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

Review 4.  Effect of hepatic insufficiency on pharmacokinetics and drug dosing.

Authors:  R K Verbeeck; Y Horsmans
Journal:  Pharm World Sci       Date:  1998-10

Review 5.  Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.

Authors:  Roger K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  2008-09-02       Impact factor: 2.953

6.  Plasma protein binding of propranolol and isoprenaline in hyperthyroidism and hypothyroidism.

Authors:  J G Kelly; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.